Stock TAKE TAKE SOLUTIONS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials TAKE Solutions Limited

Equities

TAKE

INE142I01023

Biotechnology & Medical Research

Delayed NSE India S.E.
Other stock markets
 01:39:54 2024-04-29 am EDT 		5-day change 1st Jan Change
23.4 INR -0.21% Intraday chart for TAKE Solutions Limited +6.12% +1.52%
Apr. 01 TAKE Solutions Limited Announces Resignation of P. Srinivasan as Company Secretary & Compliance Officer CI
Feb. 13 TAKE Solutions Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 21,443 21,824 5,798 6,550 4,241 1,974
Enterprise Value (EV) 1 20,241 24,060 9,916 11,656 4,730 2,330
P/E ratio 13.5 x 12.4 x -46.9 x -1.45 x -0.54 x -1.97 x
Yield 0.61% 0.67% - - - -
Capitalization / Revenue 1.35 x 1.07 x 0.26 x 0.85 x 0.65 x 1.04 x
EV / Revenue 1.28 x 1.18 x 0.45 x 1.51 x 0.72 x 1.23 x
EV / EBITDA 8.41 x 8.32 x 9.37 x -11.5 x -417 x -9.34 x
EV / FCF 465 x 43.9 x -7.25 x 6.7 x 0.8 x 0.26 x
FCF Yield 0.21% 2.28% -13.8% 14.9% 124% 389%
Price to Book 1.8 x 1.44 x 0.37 x 0.58 x 2.34 x 1.82 x
Nbr of stocks (in thousands) 131,031 146,129 146,220 145,884 146,225 146,225
Reference price 2 163.6 149.4 39.65 44.90 29.00 13.50
Announcement Date 5/17/18 7/15/19 9/3/20 7/20/21 11/29/22 7/17/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 15,872 20,390 22,129 7,740 6,552 1,891
EBITDA 1 2,408 2,891 1,058 -1,013 -11.33 -249.6
EBIT 1 2,028 2,322 20.02 -1,822 -725.3 -357.3
Operating Margin 12.78% 11.39% 0.09% -23.54% -11.07% -18.9%
Earnings before Tax (EBT) 1 1,880 2,157 -129.2 -4,388 -853.1 -452.7
Net income 1 1,605 1,773 -123.6 -4,534 -7,823 -1,003
Net margin 10.11% 8.7% -0.56% -58.58% -119.39% -53.03%
EPS 2 12.15 12.09 -0.8453 -31.01 -53.50 -6.862
Free Cash Flow 1 43.49 548.4 -1,368 1,739 5,877 9,062
FCF margin 0.27% 2.69% -6.18% 22.47% 89.7% 479.32%
FCF Conversion (EBITDA) 1.81% 18.97% - - - -
FCF Conversion (Net income) 2.71% 30.93% - - - -
Dividend per Share 2 1.000 1.000 - - - -
Announcement Date 5/17/18 7/15/19 9/3/20 7/20/21 11/29/22 7/17/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - 2,235 4,119 5,106 489 356
Net Cash position 1 1,202 - - - - -
Leverage (Debt/EBITDA) - 0.7731 x 3.893 x -5.039 x -43.18 x -1.427 x
Free Cash Flow 1 43.5 548 -1,368 1,739 5,877 9,062
ROE (net income / shareholders' equity) 14% 12.5% -0.7% -33.4% -13.6% -32.5%
ROA (Net income/ Total Assets) 7.88% 6.95% 0.05% -5.26% -2.96% -3.09%
Assets 1 20,355 25,512 -238,150 86,150 264,686 32,497
Book Value Per Share 2 91.10 104.0 108.0 76.90 12.40 7.430
Cash Flow per Share 2 21.70 3.200 3.090 2.670 1.980 0.7300
Capex 1 832 1,284 1,576 31.5 312 324
Capex / Sales 5.24% 6.3% 7.12% 0.41% 4.76% 17.13%
Announcement Date 5/17/18 7/15/19 9/3/20 7/20/21 11/29/22 7/17/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TAKE SOLUTIONS LIMITED Stock TAKE Solutions Limited
+1.52% 41.12M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TAKE Stock
  4. Financials TAKE Solutions Limited